Multi-Institutional Transgender & Gender-Diverse Breast Cancer Study

Active, not recruitingOBSERVATIONAL
Enrollment

125

Participants

Timeline

Start Date

December 8, 2023

Primary Completion Date

October 31, 2025

Study Completion Date

December 30, 2025

Conditions
Breast CancerBreast NeoplasmsBreast AdenocarcinomaBreast Cancer StageBreast Cancer Stage IVBreast Cancer InvasiveBreast Cancer in Situ
Trial Locations (22)

10012

New York University (NYU), New York

14623

University of Rochester, Rochester

19111

Fox Chase Cancer Center, Philadelphia

20007

MedStar Georgetown University Hospital (MGUH), Washington D.C.

27710

Duke University Medical Center, Durham

32224

Mayo Clinic, Jacksonville

33612

Moffitt Cancer Center (MCC), Tampa

37232

Vanderbilt University Medical Center (VUMC), Nashville

44195

Cleveland Clinic Foundation (CCF), Cleveland

48109

University of Michigan, Ann Arbor

53226

Medical College of Wisconsin, Milwaukee

55905

Mayo Clinic, Rochester

60201

NorthShore University Health System, Evanston

60611

Northwestern Medicine, Chicago

60612

Rush University Medical Center, Chicago

80045

University of Colorado Anschutz Medical Campus (CU Anschutz), Aurora

90089

University of Southern California/Los Angeles (USC/LA County), Los Angeles

94115

University of California San Francisco (UCSF), San Francisco

98195

University of Washington (UW), Seattle

02114

Massachusetts General Hospital, Boston

02115

Birgham and Women's Hospital, Boston

02118

Boston University (Boston U), Boston

All Listed Sponsors
lead

Medical College of Wisconsin

OTHER

NCT06234488 - Multi-Institutional Transgender & Gender-Diverse Breast Cancer Study | Biotech Hunter | Biotech Hunter